BRAF and metastatic melanoma: Randomized trials have shown that metastatic melanoma patients with BRAF mutation benefit from treatment with selective BRAF inhibitors—vemurafenib (Zelboraf; Roche, Basel, Switzerland) and dabrafenib (Tafinlar; GlaxoSmithKline, Research Triangle Park, NC).